The Rare Disease Bank of Japan: establishment, current status and future challenges
Research on rare diseases cannot be performed without appropriate samples from patients with such diseases. Due to the limited number of such patients, securing biosamples of sufficient quality for extensive research is a challenge and represents an important barrier to the advancement of research on rare diseases. To tackle this problem, the Rare Disease Bank (RDB) was established in 2009 at the National Institute of Biomedical Innovation (NIBIO; currently, the National Institutes of Biomedical Innovation, Health and Nutrition in Japan). Since then, the RDB has focused on three objectives: (1) emphasizing the importance of collecting biosamples from patients with rare diseases, together with appropriate clinical information, from various medical facilities nationwide; (2) maintaining strict high-quality sample management standards; and (3) sharing biosamples with research scientists across Japan for the advancement of research on rare diseases. As of August 2017, the bank has collected 4147 biosamples from patients with rare diseases, including DNA, serum, plasma, and cell samples from various university hospitals and other medical institutions across the country, and provided various research institutions with 13,686 biosample aliquots from 2850 cases. In addition, the management committee has successfully established a bank system that provides high-quality biosamples together with the results of human leukocyte antigen analysis. It is anticipated that the RDB, through the collection and sharing of biosamples with the medical research community, will enhance the understanding, prevention, and treatment of rare diseases in Japan and the world at large.
KeywordsThe Rare Disease Bank Intractable disease Biobank HLA analysis Quality control
We thank Ms. Akiko Hinomura for supporting to ethics and MTA. The authors also thank to the cooperation of patients, doctors, and medical coordinators. We would like to thank Editage (http://www.editage.jp) for English language editing. This work was funded by a grant from MHLW on Rare/Intractable Disease Project (Grant #243).
This study was funded by MHLW (JP) on Rare/Intractable Disease Project (Grant #243).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.UK Biobank. Protocol for large-scale prospective epidemiological resource. http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf (March 21, 2007) Accessed 15 Mar 2012.
- 5.Kameoka Y. Rare disease biospecimen bank. Bio Ind. 2014;28:14–21.Google Scholar
- 6.Nakagawa Y, Nakata K. Further health policy for rare/intractable diseases in Japan. J Natl Inst Public Health. 2011;60:89–93.Google Scholar
- 7.Mizusawa H. Establishment of the JCRB cell bank and quality controls of cell lines (special lectures, papers presented at the 32nd annual meeting). Jpn J Freez Dry. 1986;32:8–13.Google Scholar
- 8.Uchio-Yamada K, Koura M, Takano K, et al. Research resources bank for laboratory animals at the national institute of biomedical innovation: overview. Exp Anim. 2006;55:209.Google Scholar
- 10.Kawahara N, Kawano N, Anjiki N, et al. Recent research progress of Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition (Part 1) research project on developing of fundamental technology aiming for promotion of domestic cultivation of medicinal plants and study of medicinal plant resources for drug discovery. Pharm Med Dev Regul Sci. 2016;47:630–9.Google Scholar
- 11.Takeuchi M, Yoshida T, Enozawa S. Public human tissue bank of the human health sciences foundation. Tiss Cult Res Commun. 2004;23:39.Google Scholar
- 13.Kamatani N, Kawamoto M, Kitamura Y, Harigai M, Okumoto T, Sumino Y. Establishment of B-cell lines derived from 996 Japanese individuals. Tiss Cult Res Commun. 2004;23:71–80.Google Scholar
- 22.Kohara A, Ohtani A, Ozawa Y, Shioda S, Masui T, Mizusawa H. Report of Mycoplasma contamination in Japan. Tiss Cult Res Commun. 2007;26:159–63.Google Scholar
- 23.Masayoshi T. Outline of revised ethical guidelines for human genome/gene analysis research in Japan. Organ Biol. 2014;21:9–15.Google Scholar